Literature DB >> 20381347

The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport.

Jean-Yves Wach1, Stephan Güttinger, Ulrike Kutay, Karl Gademann.   

Abstract

An in vivo nuclear export assay (immunostaining of Rio2 in HeLa cells) demonstrated that (R)-goniothalamin is an inhibitor of nucleocytoplasmic transport above 500 nM, which was rationalized also by molecular modeling. The cytotoxic styryl lactone natural product was prepared via an enantioselective Cr(III) catalyzed hetero Diels-Alder reaction and a Sonogashira coupling. A series of analogs was synthesized and only the oxidized goniothalamin derivative featuring an alkyne spacer was found active. Unsaturated lactones of natural origin other than leptomycin (LMB) are thus suggested to operate via a similar mechanism targeting the CRM1 nuclear receptor. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381347     DOI: 10.1016/j.bmcl.2010.03.049

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

2.  Engineering chromosome region maintenance 1 fragments that bind to nuclear export signals.

Authors:  Yuqin Lei; Qi An; Yuqing Zhang; Ping Luo; Youfu Luo; Xiaofei Shen; Da Jia; Qingxiang Sun
Journal:  Protein Sci       Date:  2019-09-14       Impact factor: 6.725

3.  KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

Authors:  Julia Etchin; Takaomi Sanda; Marc R Mansour; Alex Kentsis; Joan Montero; Bonnie T Le; Amanda L Christie; Dilara McCauley; Scott J Rodig; Michael Kauffman; Sharon Shacham; Richard Stone; Anthony Letai; Andrew L Kung; A Thomas Look
Journal:  Br J Haematol       Date:  2013-02-04       Impact factor: 6.998

Review 4.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

Review 5.  Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Authors:  Giovanni Luca Gravina; William Senapedis; Dilara McCauley; Erkan Baloglu; Sharon Shacham; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

6.  Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.

Authors:  J Etchin; Q Sun; A Kentsis; A Farmer; Z C Zhang; T Sanda; M R Mansour; C Barcelo; D McCauley; M Kauffman; S Shacham; A L Christie; A L Kung; S J Rodig; Y M Chook; A T Look
Journal:  Leukemia       Date:  2012-07-31       Impact factor: 11.528

Review 7.  Structural Basis of Targeting the Exportin CRM1 in Cancer.

Authors:  Achim Dickmanns; Thomas Monecke; Ralf Ficner
Journal:  Cells       Date:  2015-09-21       Impact factor: 6.600

8.  Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.

Authors:  Shuai Wang; Xiaohong Han; Jianfei Wang; Jiarui Yao; Yuankai Shi
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

Review 9.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15

Review 10.  Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics.

Authors:  Ioanna Petta; Sam Lievens; Claude Libert; Jan Tavernier; Karolien De Bosscher
Journal:  Mol Ther       Date:  2015-12-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.